Information Provided By: 
Fly News Breaks for March 2, 2020
MGNX
Mar 2, 2020 | 07:05 EDT
Credit Suisse analyst Evan Seigerman lowered the firm's price target on MacroGenics to $17 from $26 and keeps an Outperform rating on the shares. While he continues to like the MacroGenics story, the analyst has reassessed his MacroGenics model to better reflect his view of the company' ongoing business and potential opportunity from later-stage assets including margetuximab.
News For MGNX From the Last 2 Days
There are no results for your query MGNX
